Showing 2931-2940 of 3069 results for "".
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- Medical Professionals, Practical Dermatology® Board Members, Recognized for Outstanding Work in Psoriatic Disease Fieldhttps://practicaldermatology.com/news/medical-professionals-practical-dermatology-board-members-recognized-for-outstanding-work-in-psoriatic-disease-field/2458661/Nominated by patients and colleagues, recipients of the first annual National Psoriasis Foundation Medical Professionals Awards exemplify the outstanding work being done in the psoriatic disease
- FDA Awards Tentative Approval for Zenavod to Treat Rosaceahttps://practicaldermatology.com/news/fda-awards-tentative-approval-for-zenavod-to-treat-rosacea/2458711/The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Promius™ Pharma, LLC, t
- Study Shows Novel Effects of Eucerin Active Ingredient Complex on Atopic Dermatitishttps://practicaldermatology.com/news/study-shows-novel-effects-of-eucerin-active-ingredient-complex-on-atopic-dermatitis/2458717/Beiersdorf researchers in collaboration with the Dermatological Clinic of the University of Lübeck have shown in a double-blind clinical study that the AtopiControl ingredient complex including licochalcone, a from the licorice root and omega-6 fatty acids from evening primros
- Brickell Biotech Achieves Positive Phase 2b Results for BBI-4000 for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-achieves-postive-phase-2b-results-for-bbi-4000-for-hyperhidrosis/2458772/Brickell Biotech, Inc. shared the results of its Phase 2b study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The multicenter, randomized, double blind, vehicle-controlled Phase 2b study was designed to evaluate the
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, trac
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002